CANCER IMMUNOLOGY IMMUNOTHERAPY
Scope & Guideline
Elevating Understanding of Immune Responses in Cancer
Introduction
Aims and Scopes
- Mechanisms of Immune Evasion:
Research exploring how tumors evade the immune system, including the roles of immune checkpoints, tumor microenvironment, and immune cell dynamics. - Innovative Immunotherapy Approaches:
Studies on the development and clinical application of novel immunotherapies, including monoclonal antibodies, CAR-T therapies, and oncolytic viruses. - Biomarkers for Immunotherapy Response:
Identification and validation of biomarkers that predict response to immunotherapies, aiding in personalized cancer treatment strategies. - Tumor Microenvironment Interactions:
Investigations into the interactions between tumors and immune cells in the tumor microenvironment, including the effects of cytokines and immune cell infiltration. - Clinical Trials and Outcomes:
Reports on clinical trials assessing the efficacy and safety of immunotherapies, along with patient outcomes and real-world evidence.
Trending and Emerging
- Combination Therapies:
An increasing trend towards studies that investigate the efficacy of combining immunotherapy with other treatment modalities, such as chemotherapy and targeted therapies, highlighting the potential for synergistic effects. - Personalized Immunotherapy:
A growing focus on personalized medicine approaches, including the development of neoantigen vaccines and patient-specific therapies based on genetic and immunological profiling. - Exploration of the Tumor Microbiome:
Research investigating the role of the tumor microbiome in influencing immune responses and treatment outcomes, recognizing its impact on cancer biology. - Real-World Evidence and Patient Outcomes:
A notable increase in studies providing real-world evidence on the effectiveness and safety of immunotherapies, contributing valuable insights into clinical practice. - Mechanisms of Resistance to Immunotherapy:
Emerging research on understanding the mechanisms underlying resistance to immunotherapy, aiming to identify strategies to overcome these challenges.
Declining or Waning
- Basic Research on Immune Cell Biology:
There appears to be a waning focus on fundamental studies exploring immune cell biology in isolation, as the field shifts towards translational and clinical applications. - Single-Agent Immunotherapy Studies:
Research solely focused on the efficacy of single-agent immunotherapies has decreased as combination therapies have emerged as more promising strategies. - Historical Perspectives on Immunotherapy:
There is less emphasis on historical analyses of immunotherapy developments, with a move towards current and future therapeutic innovations.
Similar Journals
MOLECULAR CANCER RESEARCH
Connecting Researchers to the Future of Cancer CareMOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Advancing the Frontiers of Immunological ResearchClinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.
CANCER GENE THERAPY
Driving Progress in Molecular Biology for Cancer SolutionsCancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.
Journal for ImmunoTherapy of Cancer
Catalyzing Change in Cancer Research and TherapyJournal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Transforming cancer research into clinical solutions.The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.
IMMUNOLOGY AND CELL BIOLOGY
Connecting Researchers in the Realm of Immunology and Cell ScienceIMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.
PATHOLOGY RESEARCH AND PRACTICE
Empowering Researchers with Cutting-Edge FindingsPATHOLOGY RESEARCH AND PRACTICE is a premier journal in the field of pathology and forensic medicine, published by Elsevier GmbH in Germany. With a rich publication history since 1978 and an impressive convergence period extending to 2024, this journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of pathological processes. It holds notable rankings, including Q3 in Cell Biology and Q2 in Pathology and Forensic Medicine for 2023, reflecting its significance in the academic community. The journal aims to publish innovative research findings, reviews, and case studies, facilitating a deeper understanding of disease mechanisms and improving diagnostic practices. Authors and readers alike benefit from its reputable platform, noted for its challenging and rigorous peer-review process. By fostering a collaborative environment and providing open access options, PATHOLOGY RESEARCH AND PRACTICE continues to contribute meaningfully to the discourse within its respective fields, thereby appealing to a diverse audience of researchers, professionals, and students.
IMMUNOLOGY LETTERS
Fostering Collaboration Through Cutting-edge ResearchIMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.
ImmunoTargets and Therapy
Catalyzing Change in Immunotherapy PracticesImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.
Cancer Immunology Research
Fostering Innovation in Cancer ImmunotherapyCancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.